Wedbush Reiterates Outperform on Apogee Therapeutics, Maintains $87 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating for Apogee Therapeutics (NASDAQ:APGE) and maintained a price target of $87.
October 25, 2024 | 3:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has reiterated an Outperform rating for Apogee Therapeutics and maintained a price target of $87, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a high price target by a reputable analyst suggests positive sentiment and potential for stock price appreciation. This is likely to boost investor confidence in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100